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OVERVIEW
The membrane-integral beta-amyloid pre-
cursor protein (βAPP) is probably the most
intensively studied brain cell protein in
neurobiology. βAPP is processed by tan-
dem beta-gamma secretase cleavage into
42 amino acid amyloid (Aβ42) peptides,
whose progressive accumulation is one
distinguishing feature of Alzheimer’s dis-
ease (AD) neuropathology (1–3). While
homeostatic amounts of Aβ42 peptide gen-
eration and clearance seem to be toler-
ated by brain cells, their over-abundance,
aggregation into higher order structures,
and inability of brain cells to effec-
tively phagocytose and clear these intensely
hydrophobic peptides contribute to the
pro-inflammatory and neurotoxic pathol-
ogy of AD. Aluminum, as an extremely
high charge density cation (Z 2/r = 18),
has the remarkable capability to both
(1) aggregate and compact Aβ42 peptide
monomers into higher order, more neu-
rotoxic oligomeric, and fibrillar structures,
and (2) impair, at the molecular-genetic
level, the cellular machinery responsible
for Aβ42 peptide monomer phagocyto-
sis and clearance from the cell (4–13).
This opinion paper will briefly assess these
two remarkable, functionally overlapping,
and decidedly neurotoxic properties of alu-
minum: (1) on the ability of physiolog-
ically realistic amounts of aluminum to
aggregate Aβ42 peptide monomers into
higher order dimeric, oligomeric, and fib-
rillar structures, and (2) on the ability of
aluminum to impair at nanomolar concen-
trations and at the level of epigenetic reg-
ulation, microglial cell-mediated clearance
mechanisms of Aβ42 peptides from the
extracellular space of the brain and CNS.
ALUMINUM, Aβ42 PEPTIDES, AND
AMYLOIDOGENESIS
The polytopic transmembrane glycopro-
tein βAPP (~770 amino acids), highly
expressed in human neurons has been
implicated as a regulator of neuronal
cytoarchitecture, synaptic plasticity, axon
guidance, and cell–cell interactions in
the brain and retina (1–3). Via tandem
beta-gamma secretase cleavage, Aβ42 pep-
tides are naturally generated as monomers
from βAPP, however, due to their
intensely lipophilic and hydrophobic char-
acter (21.4% valine–isoleucine), Aβ42
monomers rapidly aggregate into higher
order structures forming Aβ42 dimers,
oligomers, and fibrils to ultimately aggre-
gate to form the core of the senile plaque
lesions that in part characterize AD (1–
3). Factors, which accelerate Aβ42 peptide
monomer aggregation, such as aluminum
sulfate and other aluminum and metal-
lic salts, apparently do so by cross-linking
anionic amino acids contained within the
42 amino acid Aβ42 peptide sequence,
to form larger Aβ42 peptide-containing
“clumps” (1, 6). These roughly spheri-
cal deposits eventually form into dense,
insoluble senile plaques ~100µm or more
in diameter that are often visible to the
unaided eye after Congo Red or other
suitable amyloid staining (2–6). Aβ42
peptide coalescence apparently occurs in
much the same way as the aluminum
in hydrated aluminum potassium sulfate
[alum; KAl(SO4)2.12H2O], which is used
worldwide as a clarifying agent in water
purification, reacts with impurities. When
added to turbid drinking water, aluminum
crosslinks organic impurities, allowing
them to flocculate or “stick together” and
precipitate out of solution, resulting in
a highly clarified and esthetically pleas-
ing “finished” water product (14). Inter-
estingly, aggregation of Aβ42 peptides into
senile plaques can be visualized in the
living brain using multi-photon in vivo
imaging of transgenic mouse models of
AD, and can take as little as 24 h to
form, a remarkably rapid time course
in light of the fact that AD represents
such a slowly progressing neurological
disease with age-related amyloid deposi-
tion (15). In particular, interactions with
biosphere-abundant, AD-relevant metal
ions such as aluminum may lead to the
formation of highly structured amyloid
aggregates with peculiar biophysical prop-
erties that are associated with an extremely
high degree of neurotoxicity (3–6, 16–20).
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FIGURE 1 | Multiple neurotoxic actions of aluminum results in an impairment in the clearance of
Aβ42 peptides that drives amyloidogenesis and AD-type change; in intra-cellular and intra-nuclear
compartments, aluminum induces NF-kB (5, 14, 15), up-regulates miRNA-34a (9, 10), and
down-regulates TREM2, a key microglial intra-membrane phagocytic sensor protein (6–8, 11); lack of
sufficient TREM2 impairs microglial cell-mediated phagocytosis and clearance of Aβ42 peptide
monomers; deficits in TREM2 (but not the TREM2-associated TYROBP/DAP12 adaptor protein required
for phagocytosis and Aβ42 peptide engulfment) have been widely reported in AD brain and in stressed
microglial cells (7, 8, 11); in the extracellular space (upper left) aluminum aggregates Aβ42 peptide
monomers into dense insoluble spherical clumps and promotes senile plaque formation; the movement
of Al3+ across the plasma membrane is not well understood but may involve both active and passive
transport; while microglia are able to phagocytose Aβ42 peptide monomers that they may have
difficulty with higher order aggregates resulting in microglial activation and a pathogenic
pro-inflammatory response that contributes to AD neuropathology.
Aluminum’s stimulatory effects on such
AD-type neuropathology are further sup-
ported by the observation that trans-
genic murine models for AD (TgAD),
such as the amyloid-overexpressing Tg2576
model, when fed aluminum in their diet,
exhibit increased oxidative stress, pro-
inflammatory signaling, and even more
robust senile plaque lesion formation com-






Active microglial cell-mediated phago-
cytic processes that remove excessive,
neurotoxic, or end-stage molecules from
the brain are a naturally occurring
mechanism to cleanse the neural environ-
ment and maintain neural homeostasis (7–
11). Failure of these continuous homeo-
static phagocytic processes has potential
pro-inflammatory, innate-immune, and
neuropathogenic consequences (8–13, 20).
Interestingly, microglial cells, the “roving
phagocytic scavengers” of the human brain
and CNS surround aggregating Aβ42 pep-
tides and when so activated appear to play a
role in inflammatory and immune aspects
of AD pathogenesis including the further
generation of brain cell-damaging reac-
tive oxygen species (ROS) (5, 17–19). One
key microglial transmembrane-spanning
stimulatory sensor–receptor glycoprotein
of the immune-globulin/lectin-like gene
superfamily essential for phagocytosis
of Aβ42 peptides in the brain and
CNS is the inducible triggering recep-
tor expressed in myeloid/microglial cells
(TREM2; Figure 1) (7–13). This gly-
coprotein, an important player in the
CNS innate-immune response extends
molecular sensors into the extracellu-
lar environment to sense and recognize
molecular tags located on Aβ42 pep-
tides – this is accomplished by poorly
understood molecular-pattern recogni-
tion mechanisms (Figure 1) (10–13).
Aluminum sulfate, a known stimulator
of ROS and the pro-inflammatory tran-
scription factor NF-kB, is also known to
induce a small family of pro-inflammatory
microRNAs including miRNA-34a (7–
12). An up-regulated miRNA-34a in turn
down-regulates TREM2 expression in the
microglial cell membrane leading to a
deficit in the ability of microglial cells
to effectively phagocytose Aβ42 peptide
monomers (9, 10, 13). This ultimately
results in a buildup of Aβ42 peptides in
the extracellular space, and thus favors their
self-aggregation into higher order amyloid
species (Figure 1).
Taken together, these results strongly
suggest that one of the most prominent
features of AD – the progressive accumu-
lation and aggregation of Aβ42 peptides
into senile plaques – is driven by alu-
minum via multiple interdependent path-
ogenic mechanisms. These findings con-
tinue to support an active role for alu-
minum in key neuropathogenic, inflam-
matory, and amyloidogenic pathways that
contribute to the AD process. Aluminum
appears to therefore drive AD-relevant
amyloidogenic pathology (1) directly, by
aggregation of Aβ42 peptide monomers
into higher order structures that subse-
quently form into senile plaque cores, and
(2) indirectly, through an NF-kB- and
miRNA-34a-mediated epigenetic mecha-
nism that contributes to a down-regulation
in the expression of the key phagocyto-
sis sensor protein TREM2, and a failure of
microglial cells to naturally sense, phagocy-
tose, and eliminate neurotoxic Aβ42 pep-
tides. Hence, both of these pathways have
strong potential to contribute, perhaps
cooperatively, to the failure to adequately
phagocytose naturally generated Aβ42 pep-
tide monomers, thus promoting their
aggregation and driving amyloidogene-
sis with pro-inflammatory consequences.
Indeed, the aluminum-mediated aggre-
gation of Aβ42 peptide monomers into
higher order structures of higher molec-
ular mass may preclude them from being
adequately “ingested” by microglial cell-
mediated phagocytic mechanisms, further
supporting their accumulation and self-
association in the extracellular space. It
will certainly be interesting to see if alu-
minum salts perform similar pathogenic
roles in other progressive, age-related neu-
rodegenerative disorders of the CNS with
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an innate-immune, inflammatory, and/or
amyloidogenic component.
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